tbuckley/cabot-search huggingface dataset:
Direct microglia replacement reveals pathologic and therapeutic contributions of brain macrophages to a monogenic neurological disease
Authors: William H Aisenberg, Carleigh A O'Brien, Madison Sangster, Fazeela Yaqoob, Yuanchao Zhang, Brian Temsamrit, Searlait Thom, Luca Gosse, Sai Chaluvadi, Bilal Elfayomi, Gavin Lee, Vidhur Polam, Eli M Levitt, Gary Liu, Sonia I Lombroso, Kelsey M Nemec, Gavin Clowry, Cassaundra Nieves, Priyanka Rawat, Emily Church, Daniel Martinez, Clarissa Shoffler, Daliya Kancheva, Christopher Petucci, Deanne Taylor, Julia Kofler, Daniel Erskine, Kiavash Movahedi, Mariko L Bennett, F Chris Bennett
Journal: Immunity (2025)
Chemotherapy-free neoadjuvant pembrolizumab combined with trastuzumab and pertuzumab in HER2-enriched early breast cancer (WSG-KEYRICHED-1): a single-arm, phase 2 trial
Authors: Sherko Kuemmel, Monika Graeser, Peter Schmid, Mattea Reinisch, Friedrich Feuerhake, Valery Volk, Sorin Armeanu-Ebinger, Leon Schütz, Olga Kelemen, Christopher Schroeder, Stephan Ossowski, Katarzyna Jóźwiak, Athina Kostara, Iris Scheffen, Kerstin Lüdtke-Heckenkamp, Felix Hilpert, Angela Kentsch, Carsten Ziske, Reinhard Depenbusch, Michael Braun, Jens Uwe Blohmer, Christine Zu Eulenburg, Matthias Christgen, Stephan Bartels, Hans Heinrich Kreipe, Rachel Wuerstlein, Claudia Biehl, Enrico Pelz, Andreas Hartkopf, Nadia Harbeck, Oleg Gluz
Journal: The Lancet Oncology (2025)
Corrigendum to “Opposite evolution of pathogenicity driven by in vivo wzc and wcaJ mutations in ST11-KL64 carbapenem-resistant Klebsiella pneumoniae” [Drug Resist. Updat. 66 (2023) 100891]
Authors: Jintao He, Qiucheng Shi, Zhifu Chen, Wang Zhang, Peng Lan, Qingye Xu, Huangdu Hu, Qiong Chen, Jianzhong Fan, Yan Jiang, Belinda Loh, Sebastian Leptihn, Quanming Zou, Jinyong Zhang, Yunsong Yu, Xiaoting Hua
Journal: Drug Resistance Updates (2025)
Incidence and prevalence of antimicrobial resistance in outpatients with cancer: a multicentre, retrospective, cohort study
Authors: Vikas Gupta, Michael J Satlin, Kalvin C Yu, Yehoda Martei, Lillian Sung, Lars F Westblade, Scott Howard, ChinEn Ai, Diane C Flayhart
Journal: The Lancet Oncology (2025)
International consensus on laryngeal preservation strategies in laryngeal and hypopharyngeal cancer
Authors: Marco Ferrari, Francesca Mularoni, Davide Smussi, Piergiorgio Gaudioso, Pierluigi Bonomo, Jeppe Friborg, Maria Grazia Ghi, Vincent Gregoire, Kevin Harrington, Keith Hunter, Roberto Maroldi, Rosemary Martino, Ricard Mesia, Giorgio Peretti, Amanda Psyrri, Antonio Schindler, Giovanni Succo, Petr Szturz, Isabel Vilaseca, Piero Nicolai, Paolo Bossi
Journal: The Lancet Oncology (2025)
Antimicrobial resistance in patients with haematological malignancies: a scoping review
Authors: Ya Haddy Sallah, Vanessa F Bratti, Bahar Rafinejad-Farahani, Shalini Jayasekar Zurn, Sonali Johnson, André S Crestani, Maria I Dacoregio, Haris Majeed, Rouhi Fazelzad, Aliyah Pabani, Brooke E Wilson, Fernanda M Favorito, Fabio Ynoe de Moraes, Lillian Sung, Yehoda M Martei, Danielle Rodin
Journal: The Lancet Oncology (2025)
Pseudogout, chondrocalcinosis, CPPD et al: crystal clear… or clear as mud?–The time has come to reconsider the nomenclature of calcium pyrophosphate deposition
Authors: Silvia Sirotti, Charlotte Jauffret, Antonella Adinolfi, Edoardo Cipolletta, Daniele Cirillo, Luca Ingrao, Alessandro Lucia, Emilio Filippucci, Tristan Pascart, Sara K Tedeschi, Robert Terkeltaub, Nicola Dalbeth, Georgios Filippou
Journal: Annals of the Rheumatic Diseases (2025)

Scientific interest in calcium pyrophosphate deposition (CPPD) has been limited by several challenges. These include difficulties in diagnosis due to diverse clinical presentations, the lack of classification criteria, the absence of standardised diagnostic modalities, underrecognition in clinical care, and, most significantly, the lack of evidence-based treatments. Consequently, CPPD was often regarded as the 'poor cousin' of gout. Fortunately, in recent years, CPPD has garnered increased attention from the rheumatology community. Milestones such as the first American College of Rheumatology/European Alliance of Association for Rheumatology classification criteria, the European Alliance of Association for Rheumatology recommendations for the use of imaging in clinical practice, validated OMERACT ultrasound definitions and scoring system, and the OMERACT core domain sets for CPPD have significantly advanced the field. Yet, unresolved issues regarding CPPD nomenclature hold back advancement in both research and clinical practice. The terminology surrounding CPPD remains inconsistent in the scientific literature, with numerous terms and acronyms used to describe the condition and its manifestations. For example, many 'pseudosyndromes' (eg, pseudogout) and purely radiographic descriptors (eg, chondrocalcinosis) are still commonly used by clinicians and researchers interchangeably, as either the name of the condition or one of its clinical or radiographic manifestations. This lack of standardisation complicates communication among health care professionals, researchers, and between doctors and patients, creating insurmountable barriers to effective care and research advances. In this viewpoint, we highlight the value of standardised terminology, drawing parallels with other rheumatic diseases. We aimed to explore the historical evolution of CPPD nomenclature, assess the impact of previous standardisation efforts, and propose a possible way for a common language.
Re: Thomas van Doeveren, Sebastiaan Remmers, Egbart R. Boevé, et al. Intravesical Instillation of Chemotherapy Before Radical Surgery for Upper Urinary Tract Urothelial Carcinoma: The REBACARE Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2024.12.006
Authors: Joren Vanthoor, Joyce Baard, Olivier Traxer, Vincent De Coninck
Journal: European Urology (2025)
Relapse after anti-CD19 CAR T-cell therapy in a patient with severe rheumatoid arthritis and multiple sclerosis effectively treated by autologous stem cell transplantation
Authors: Ann-Christin Pecher, Luca Hensen, Rebekka Schairer-Marquardt, Markus Kowarik, Vivien Richter, Wolfgang Bethge, Claudia Lengerke, Jörg Henes
Journal: Annals of the Rheumatic Diseases (2025)
Charting the Single-Cell and Spatial Landscape of IDH-Wildtype Glioblastoma with GBmap
Authors: Cristian Ruiz-Moreno, Sergio Marco Salas, Erik Samuelsson, Mariia Minaeva, Ignacio Ibarra, Marco Grillo, Sebastian Brandner, Ananya Roy, Karin Forsberg-Nilsson, Mariette E G Kranendonk, Fabian J Theis, Mats Nilsson, Hendrik G Stunnenberg
Journal: Neuro-Oncology (2025)

Abstract Background Glioblastoma (GB), particularly IDH-wildtype, is the most aggressive brain malignancy with a dismal prognosis. Despite advances in molecular profiling, the complexity of its tumor microenvironment and spatial organization remains poorly understood. This study aimed to create a comprehensive single-cell and spatial atlas of GB to unravel its cellular heterogeneity, spatial architecture, and clinical relevance. Methods We integrated single-cell RNA sequencing data from 26 datasets, encompassing over 1.1 million cells from 240 patients, to construct GBmap, a harmonized single-cell atlas. High-resolution spatial transcriptomics was employed to map the spatial organization of GB tissues. We developed the Tumor Structure Score (TSS) to quantify tumor organization and correlated it with patient outcomes. Results We showcase the applications of GBmap for reference mapping, transfer learning, and biological discoveries. GBmap revealed extensive cellular heterogeneity, identifying rare populations such as tumor-associated neutrophils and homeostatic microglia. Spatial analysis uncovered seven distinct tumor niches, with hypoxia-dependent niches strongly associated with poor prognosis. The TSS demonstrated that highly organized tumors, characterized by well-defined vasculature and hypoxic niches, correlated with worse survival outcomes. Conclusions This study provides a comprehensive resource for understanding glioblastoma heterogeneity and spatial organization. GBmap and the TSS provide an integrative view of tumor architecture in GB, highlighting hypoxia-driven niches that may represent avenues for further investigation. Our resource can facilitate exploratory analyses and hypothesis generation to better understand disease progression.
CD22 CAR-T cells secreting CD19 T-cell engagers for improved control of B-cell acute lymphoblastic leukemia progression
Authors: Javier Arroyo-Ródenas, Aida Falgas, Laura Díez-Alonso, Alba Martinez-Moreno, Heleia Roca-Ho, Francisco J Gil-Etayo, Alba Pérez-Pons, Óscar Aguilar-Sopeña, Miriam Velasco-Sidro, Marina Gómez-Rosel, Beatriz Jiménez-Matías, Guillermo Muñoz-Sánchez, Yedra Pacheco, Clara Bravo-Martín, Ángel Ramírez-Fernández, Anaïs Jiménez-Reinoso, Europa Azucena González-Navarro, Manel Juan, Alberto Orfao, Belén Blanco, Pedro Roda-Navarro, Clara Bueno, Pablo Menéndez, Luis Álvarez-Vallina
Journal: Journal for ImmunoTherapy of Cancer (2025)

Background CD19-directed cancer immunotherapies, based on engineered T cells bearing chimeric antigen receptors (CARs, CAR-T cells) or the systemic administration of bispecific T cell-engaging (TCE) antibodies, have shown impressive clinical responses in relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL). However, more than half of patients relapse after CAR-T or TCE therapy, with antigen escape or lineage switching accounting for one-third of disease recurrences. To minimize tumor escape, dual-targeting CAR-T cell therapies simultaneously targeting CD19 and CD22 have been developed and validated both preclinically and clinically. Methods We have generated the first dual-targeting strategy for B-cell malignancies based on CD22 CAR-T cells secreting an anti-CD19 TCE antibody (CAR-STAb-T) and conducted a comprehensive preclinical characterization comparing its therapeutic potential in B-ALL with that of previously validated dual-targeting CD19/CD22 tandem CAR cells (TanCAR-T cells) and co-administration of two single-targeting CD19 and CD22 CAR-T cells (pooled CAR-T cells). Results We demonstrate that CAR-STAb-T cells efficiently redirect bystander T cells, resulting in higher cytotoxicity of B-ALL cells than dual-targeting CAR-T cells at limiting effector:target ratios. Furthermore, when antigen loss was replicated in a heterogeneous B-ALL cell model, CAR-STAb T cells induced more potent and effective cytotoxic responses than dual-targeting CAR-T cells in both short- and long-term co-culture assays, reducing the risk of CD19-positive leukemia escape. In vivo, CAR-STAb-T cells also controlled leukemia progression more efficiently than dual-targeting CAR-T cells in patient-derived xenograft mouse models under T cell-limiting conditions. Conclusions CD22 CAR-T cells secreting CD19 T-cell engagers show an enhanced control of B-ALL progression compared with CD19/CD22 dual CAR-based therapies, supporting their potential for clinical testing.
Tumor-infiltrating mast cells as potential chemoimmunotherapy enhancer in triple-negative breast cancer
Authors: Pinchao Fan, Chengjun Zhu, Xiaoxiang Guan
Journal: Journal for ImmunoTherapy of Cancer (2025)

Over the past decade, combining immune checkpoint blockade with chemotherapy has reshaped the paradigm of triple-negative breast cancer (TNBC), but the cellular dynamics in the tumor immune microenvironment (TIME) that orchestrate clinical response remain elusive. In a recent issue of Cancer Cell , Zhang et al integrated murine and human single-cell sequencing data, and unveiled that tumor-infiltrating mast cells (TIMCs) could exert distinct antitumor effects by enriching and fueling various immune cell clusters, suggesting the pivotal tuning role of TIMCs in the TIME of TNBC, as well as paving promising avenues for future TIMC-targeting therapies in synergy with chemoimmunotherapy against TNBC.
Monitoring neurodegeneration through brain-derived extracellular vesicles in biofluids
Authors: Francesca Torrini, Marcos Gil-Garcia, Jacopo Cardellini, Roberto Frigerio, Manuela Basso, Alessandro Gori, Paolo Arosio
Journal: Trends in Pharmacological Sciences (2025)

The identification of neurodegenerative disease (ND) biomarkers in easily accessible body fluids is crucial in the fight against this class of disorders. Brain-derived extracellular vesicles (BDEVs) have gained attention as nanoscale carriers of molecular information and bioactive molecules that reflect the status of their source cells. By crossing the blood-brain barrier (BBB), BDEVs can transfer these biomolecular signatures to peripheral biofluids, setting the scene for their use as ND biomarkers. In this review, we explore the role of BDEVs in liquid biopsy as a promising route for early ND diagnosis, as well as patient stratification and follow-up, with a particular focus on their ability to transport misfolded proteins and protein aggregates, major actors in neurodegeneration development. We also discuss the link between the physicochemical properties of BDEVs and the potential insights gained into NDs, highlighting both challenges and opportunities associated with the use of BDEVs for ND diagnostics.
Underlying health biases in previously-infected SARS-CoV-2 vaccination recipients: a cohort study
Authors: Uwe Riedmann, Alena Chalupka, Lukas Richter, Dirk Werber, Martin Sprenger, Peter Willeit, Marc Rijksen, Julia Lodron, Tracy Beth Høeg, John Pa Ioannidis, Stefan Pilz
Journal: Journal of Infection (2025)

Observational studies may over- or under-estimate SARS-CoV-2 vaccine effectiveness (VE) depending on whether healthier (i.e. healthy vaccine effect (HVE)) or more ill individuals are preferentially vaccinated. To evaluate this issue, we compared non-COVID-19 mortality in vaccinated versus unvaccinated individuals. This is a nationwide retrospective observational study in the entire adult population in Austria with previously documented SARS-CoV-2 infection with a follow-up from 2021 to 2023. Cox regression analyses were used to calculate hazard ratios (HRs) according to the number of SARS-CoV-2 vaccinations. We also performed matched analyses, where on each day, newly vaccinated individuals were matched with unvaccinated individuals based on age, sex and nursing home residency. In 4,324,485 eligible individuals, differences in non-COVID-19 mortality risk between vaccinated and unvaccinated were most prominent in the early periods and decreased thereafter. Matched analyses for the first two weeks after vaccination showed HRs below 0.5 for vaccinated versus unvaccinated individuals irrespective of vaccination numbers. Similar findings were retrieved for non-COVID-19, all-cause, and cancer deaths. Overall, COVID-19 deaths were significantly reduced in vaccinated individuals (VE of 26 to 53%). HVE for SARS-CoV-2 vaccines was strong early after vaccination and diminished over time. HVE should be considered when estimating VE.
Re: Steven MacLennan, Oliver Wiseman, Daron Smith, et al. Updated Systematic Review and Meta-analysis of Extracorporeal Shock Wave Lithotripsy, Flexible Ureterorenoscopy, and Percutaneous Nephrolithotomy for Lower Pole Renal Stones. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2025.01.020
Authors: Yalong Zhang, Rui Yan, Li Yang
Journal: European Urology (2025)
Transgenic human nephrin in Drosophila nephrocytes facilitates variant analysis.
Authors: Julia Melina Wolff, Konrad Lang, Mengmeng Chen, Julian Milosavljevic, Séverine Kayser, Martin Helmstädter, Gerd Walz, Ahmed Abed, Lea Gerstner, Sami Bahar, Maximilian H Ulbrich, Tobias Hermle
Journal: Kidney International (2025)
Combined Liver with Other Solid Organ Transplants: Promises, Pitfalls and ethical dilemmas, An Expert Opinion
Authors: Francesco Paolo Russo, Sarwa Darwish Murad, Anjana A Pillai, Alexandra Shingina, Laura Donahoe, Anna Mrzljak, Yaron Avitzur, Patrizia Burra, Nazia Selzner
Journal: Journal of Hepatology (2025)
Hepatocellular carcinoma in people living with HIV
Authors: Claudia Am Fulgenzi, Alessia Dalla Pria, Alberto Giovanni Leone, Ciro Celsa, Giuseppe Cabibbo, Bernhard Scheiner, Matthias Pinter, Antonio D'Alessio, Yiran Zhao, Norbert Brau, Mark Bower, David James Pinato
Journal: Journal of Hepatology (2025)

People living with HIV (PLWH) carry a higher risk of developing chronic liver disease and hepatocellular carcinoma (HCC). This relates to shared transmission pathways of HIV and viral hepatitis and a plethora of direct and indirect effects of HIV in the progression of chronic liver disease and HCC. In absence of active cancer treatment, the prognosis of PLWH affected by HCC is worse compared to matched controls without HIV. Evolving evidence suggests that PLWH may receive curative therapies including liver transplantation, loco-regional and systemic anti-cancer therapy for HCC with comparable benefit than people without HIV, underscoring that well controlled HIV infection should not be a barrier to the delivery of cancer care. Nevertheless, PLWH have historically been excluded from interventional clinical trials, and most of the evidence supporting clinical decision making in this population comes from small retrospective studies, adding further challenges to the management of PLWH affected by HCC. Furthermore, whether the biology of the tumour and its microenvironment is influenced by HIV and affects response to treatment is incompletely understood. In this review we summarise the current understanding of pathophysiology, screening and management of HCC in PLWH and discuss the persisting challenges and disparities in care which may contribute to clinical outcome in PLWH.
Discordance between measures of Mycobacterium tuberculosis sensitization and type 2 diabetes mellitus in the United States (NHANES): a population-based cohort study
Authors: Itai M Magodoro, Katalin A Wilkinson, Brian L Claggett, Ntobeko A B Ntusi, Mark J Siedner M, Robert J Wilkinson
Journal: Journal of Infection (2025)

We examined how latent TB infection (LTBI), evaluated by cell-mediated immune responses to Mycobacterium tuberculosis (Mtb) antigens, impacts glucose metabolism in US adults. Mtb sensitization was evaluated by interferon-γ (IFN-γ) release assay (IGRA+: assay reactivity) and tuberculin skin testing (TST+: skin induration ≥10mm), and categorized as: IGRA-/TST- (TB uninfected controls); IGRA-/TST+; IGRA+/TST-; or IGRA+/TST+. Diabetes was ascertained by fasting plasma glucose (FPG) ≥7.0mmol/L, HbA1c ≥6.5% and/or antidiabetic medication. Adjusted generalized additive models examined nonlinear effects of skin induration and IFN-γ reactivity on FPG and HbA1c; and LTBI on diabetes prevalence. Among 1,787 (IGRA-/TST-), 101 (IGRA-/TST+), 92 (IGRA+/TST-), and 99 (IGRA+/TST+) adults, skin induration linearly associated with FPG [effective degrees of freedom (EDF) =1.01; p<0.001] and non-linearly with HbA1c [EDF=1.76; p=0.003]. IFN-γ reactivity correlated with neither FPG [p=0.58] nor HbA1c [p=0.94]. Relatedly, adjusted diabetes prevalence was greater in IGRA-/TST+ [24.9%; p=0.048] and IGRA+/TST+ [27.3%; p=0.004] but not IGRA+/TST- [15.9%; p=0.69] individuals than among controls [15.3%]. LTBI associated with glycemic measures and diabetes when assessed by skin induration, but not IFN-γ release. This suggests an association with innate immune activation rather than acquired T-cell response, as determined by ex vivo IFN-γ release assay.
LONG TERM EFFECTS OF COVID-19 IN PRIMARY IMMUNODEFICIENCY PATIENTS: AN IPOPI WORLDWIDE SURVEY
Authors: Leanne P M van Leeuwen, Samya Van Coillie, Johan Prévot, Jose Drabwell, Nizar Mahlaoui, Silvia Sánchez-Ramón, M Cecilia Poli, Isabelle Meyts, Adli Ali, David M Lowe, Virgil A S H Dalm, Martine Pergent
Journal: Journal of Allergy and Clinical Immunology (2025)
Osteoclasts drive bone formation in ectopic and orthotopic environments
Authors: Yang Zhang, Taozhao Yu, Qianfeng Xiang, Femke van den Tillaart, Jinling Ma, Zhumei Zhuang, Talita Stessuk, Huanan Wang, Jeroen J J P van den Beucken
Journal: Biomaterials (2025)

To date, cell-based approaches to stimulate bone formation have primarily focused on mesenchymal stromal cells (MSCs) for their supposed osteogenic potential, but despite some pre-clinical successes, clinical outcomes have remained unsatisfactory. Emerging data suggest that osteoclasts play crucial roles in stimulating bone formation beyond their catabolic function in bone resorption. Interestingly, osteoclastic activity precedes osteoblastic bone formation in the physiological bone remodeling cycle. To explore the role of osteoclasts in bone formation further, we prepared osteoclast-based constructs and implanted them (i) ectopically to evaluate their potential to induce bone formation, and (ii) orthotopically to evaluate effects on bone regeneration. Remarkably, constructs containing primary mouse osteoclasts showed consistent and robust de novo bone formation, which presented comparable osteogenic efficacy to BMP-2 treatment. Additionally, we observed de novo bone marrow formation upon ectopic implantation of osteoclast-based constructs (incidence 73 %) and BMP-2 loaded controls (incidence 91 %). Importantly, constructs containing macrophages (MФs) or scaffold only (negative control) showed neither bone nor bone marrow formation. Further, a mouse cranial defect model confirmed the stimulatory bone regeneration capabilities of Osteoclast-based constructs, evidenced by 2.5-fold increased bone formation compared to scaffold only. These findings demonstrate the osteoinduction and osteogenesis capacity of osteoclasts, reshaping our understanding of their role in bone formation and opening new avenues for the design and development of cell-based constructs for bone repair.
Stepwise neofunctionalization of the NF-κB family member Rel during vertebrate evolution
Authors: Allison E Daly, Abraham B Chang, Prabhat K Purbey, Kevin J Williams, Shuxing Li, Benjamin D Redelings, George Yeh, Yongqing Wu, Scott D Pope, Byrappa Venkatesh, Sibon Li, Kaylin Nguyen, Joseph Rodrigues, Kelsey Jorgensen, Ananya Dasgupta, Trevor Siggers, Lin Chen, Stephen T Smale
Journal: Nature Immunology (2025)

Adaptive immunity and the five vertebrate NF-κB family members first emerged in cartilaginous fish, suggesting that NF-κB family divergence helped to facilitate adaptive immunity. One specialized function of the NF-κB Rel protein in macrophages is activation of Il12b, which encodes a key regulator of T cell development. We found that Il12b exhibits much greater Rel dependence than inducible innate immunity genes in macrophages, with the unique function of Rel dimers depending on a heightened intrinsic DNA-binding affinity. Chromatin immunoprecipitation followed by sequencing experiments defined differential DNA-binding preferences of NF-κB family members genome-wide, and X-ray crystallography revealed a key residue that supports the heightened DNA-binding affinity of Rel dimers. Unexpectedly, this residue, the heightened affinity of Rel dimers, and the portion of the Il12b promoter bound by Rel dimers were largely restricted to mammals. Our findings reveal major structural transitions in an NF-κB family member and one of its key target promoters at a late stage of vertebrate evolution that apparently contributed to immunoregulatory rewiring in mammalian species.
Towards precision medicine in clinical trials for the treatment of urologic chronic pelvic pain syndrome: lessons from the MAPP Research Network
Authors: Alisa J Stephens Shields, J Quentin Clemens, Michel A Pontari, H Henry Lai, Robert Moldwin, David A Williams, Catherine S Bradley, John T Farrar, J Richard Landis, Chris Mullins, Bruce D Naliboff, Siobhan Sutcliffe, Stephen J Walker, Claire C Yang, Daniel J Clauw
Journal: Nature Reviews Urology (2025)
Aberrant T follicular helper cells generated by TH17 cell plasticity in the gut promote extraintestinal autoimmunity
Authors: Tingting Fan, Chi Tai, Kiah C Sleiman, Madeline P Cutcliffe, Haram Kim, Ye Liu, Jianying Li, Gang Xin, Mollyanna Grashel, Laurie Baert, Chinwe Ekeocha, Paige Vergenes, Svetlana Lima, Wan-Lin Lo, Judith Lin, Beatriz Hanaoka, Trevor N Tankersley, Min Wang, Xuan Zhang, George C Tsokos, Wael Jarjour, Randy Longman, Hsin-Jung Joyce Wu
Journal: Nature Immunology (2025)